West Pharmaceutical Services Names Robert McMahon New CFO to Enhance Financial Strategies
- West Pharmaceutical Services appointed Robert McMahon as CFO, effective August 4, 2025, succeeding Bernard Birkett.
- McMahon brings 34 years of healthcare financial experience, previously serving as CFO at Agilent Technologies.
- He aims to enhance West's growth and shareholder value while driving innovation in injectable drug administration solutions.
West Pharmaceutical Services Appoints New CFO to Drive Financial Strategy Forward
West Pharmaceutical Services, Inc. announces the appointment of Robert McMahon as its new Chief Financial Officer (CFO), effective August 4, 2025. This strategic move comes as the company prepares for the retirement of Bernard Birkett, who will assist in the transition as a Senior Advisor until the end of the year. McMahon arrives with a wealth of experience from a distinguished 34-year career in the healthcare industry, most recently serving as the CFO at Agilent Technologies Inc. since 2018. During his tenure there, he demonstrated expertise in overseeing a range of financial operations including audit, treasury, tax, investor relations, IT, and procurement.
Throughout his career, McMahon has held significant roles at renowned companies such as Hologic, Inc. and Johnson & Johnson, where he spent two decades cultivating a robust understanding of financial management in dynamic environments. His extensive background equips him with the skills necessary to navigate the complex financial landscape of the healthcare sector. Eric M. Green, President and CEO of West, expresses confidence in McMahon's ability to drive financial transformation and deliver strong results. He believes that McMahon’s strategic mindset will be instrumental in enhancing the company's operational effectiveness and ongoing innovation in injectable drug administration solutions.
In his new role, McMahon emphasizes his enthusiasm for joining West Pharmaceutical Services, recognizing the company’s long-standing commitment to improving patient health through innovative solutions. He aims to collaborate closely with the leadership team to bolster the company’s growth trajectory and enhance shareholder value. This leadership transition is a critical element in West’s ongoing efforts to strengthen its financial strategies while maintaining its reputation as a leader in high-quality injectable solutions for both established and emerging pharmaceutical companies.
Beyond the leadership change, West Pharmaceutical Services continues to focus on its core mission of advancing injectable drug administration solutions. The company's commitment to innovation and quality positions it favorably in a competitive market, enabling it to serve a diverse portfolio of pharmaceutical clients effectively. As the industry evolves, West remains dedicated to meeting the emerging needs of healthcare providers and patients, ensuring that it remains at the forefront of pharmaceutical delivery technology.